Valeo Pharma
-
Record revenues in 2022 of $27.7 million, Valeo Pharma investment in commercial infrastructure starts to pay off
What a difference a year makes. Last year at this time we were heading into wave something or…
-
Steve Saviuk on how Valeo Pharma’s ‘life changing’ products have delivered the strong growth forecasted for 2022
In this InvestorIntel interview, Tracy Weslosky interviews Valeo Pharma Inc.’s (TSX: VPH | OTCQB: VPHIF) Founder, CEO and…
-
Valeo Pharma keeps delivering with a 100% revenue growth forecast in 2022 and more new effective pharmaceuticals
Early in 2022 InvestorIntel updated readers about a company that was growing its revenue at an incredible rate…
-
Steve Saviuk of Valeo Pharma talks about acquiring new therapeutic drugs and record Q3 revenue
In this interview, InvestorIntel Publisher and Editor in Chief Stephen Lautens talks to Valeo Pharma Inc.’s (TSX: VPH…
-
Valeo Pharma’s Steve Saviuk talks about the US$40M non-dilutive financing from Sagard Healthcare Partners
In this InvestorIntel interview with host Tracy Weslosky, Valeo Pharma Inc.’s (TSX: VPH | OTCQB: VPHIF) Founder, CEO and…
-
Steve Saviuk of Valeo Pharma talks about revenue growth following impressive market gains
In this InvestorIntel interview with host Tracy Weslosky, Valeo Pharma Inc.’s (TSX: VPH | OTCQB: VPHIF) Founder, CEO…
-
Valeo Pharma revenues jump on increased market share from growing drug portfolio
Valeo Pharma Inc. (TSX: VPH | OTCQB: VPHIF) is a Canadian pharmaceutical company that is seeing significant success…
-
Steve Saviuk on Valeo Pharma’s TSX Listing and Q1-22 revenues of $4.2 million, up 128% over Q1-21
In a recent InvestorIntel interview, Tracy Weslosky interviews Valeo Pharma Inc.’s (TSX: VPH | OTCQB: VPHIF) Founder, CEO…
-
Valeo Pharma’s rocketing growth in sales points to positive cash flow this year
Stock market investors love companies that can quickly expand and rapidly grow their revenues. The very best of…
